DNA vs. FUSN, NVAX, CGON, SANA, INBX, BEAM, ADMA, KYMR, NMRA, and APGE
Should you be buying Ginkgo Bioworks stock or one of its competitors? The main competitors of Ginkgo Bioworks include Fusion Pharmaceuticals (FUSN), Novavax (NVAX), CG Oncology (CGON), Sana Biotechnology (SANA), Inhibrx (INBX), Beam Therapeutics (BEAM), ADMA Biologics (ADMA), Kymera Therapeutics (KYMR), Neumora Therapeutics (NMRA), and Apogee Therapeutics (APGE). These companies are all part of the "biological products, except diagnostic" industry.
Fusion Pharmaceuticals (NASDAQ:FUSN) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.
Fusion Pharmaceuticals has higher earnings, but lower revenue than Ginkgo Bioworks. Fusion Pharmaceuticals is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.
Fusion Pharmaceuticals received 18 more outperform votes than Ginkgo Bioworks when rated by MarketBeat users. Likewise, 64.06% of users gave Fusion Pharmaceuticals an outperform vote while only 47.92% of users gave Ginkgo Bioworks an outperform vote.
In the previous week, Ginkgo Bioworks had 20 more articles in the media than Fusion Pharmaceuticals. MarketBeat recorded 30 mentions for Ginkgo Bioworks and 10 mentions for Fusion Pharmaceuticals. Ginkgo Bioworks' average media sentiment score of 0.34 beat Fusion Pharmaceuticals' score of 0.15 indicating that Fusion Pharmaceuticals is being referred to more favorably in the media.
72.9% of Fusion Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 7.8% of Fusion Pharmaceuticals shares are owned by insiders. Comparatively, 15.1% of Ginkgo Bioworks shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Fusion Pharmaceuticals has a beta of -0.69, suggesting that its share price is 169% less volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.
Ginkgo Bioworks has a net margin of -409.11% compared to Ginkgo Bioworks' net margin of -4,136.55%. Ginkgo Bioworks' return on equity of -48.74% beat Fusion Pharmaceuticals' return on equity.
Fusion Pharmaceuticals presently has a consensus price target of $20.25, indicating a potential downside of 5.99%. Ginkgo Bioworks has a consensus price target of $1.90, indicating a potential upside of 125.68%. Given Fusion Pharmaceuticals' higher possible upside, analysts plainly believe Ginkgo Bioworks is more favorable than Fusion Pharmaceuticals.
Summary
Ginkgo Bioworks beats Fusion Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Ginkgo Bioworks News Delivered to You Automatically
Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ginkgo Bioworks Competitors List
Related Companies and Tools
